Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Sells $485,771.97 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg sold 2,103 shares of the stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total value of $485,771.97. Following the sale, the chief marketing officer now directly owns 15,609 shares in the company, valued at $3,605,522.91. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Alnylam Pharmaceuticals Trading Down 1.6 %

Shares of ALNY opened at $243.00 on Friday. The business’s 50 day moving average is $159.86 and its 200 day moving average is $164.73. The company has a market capitalization of $30.74 billion, a PE ratio of -90.67 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $252.87.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.23. The business had revenue of $494.33 million for the quarter, compared to the consensus estimate of $428.01 million. The firm’s revenue for the quarter was up 54.8% compared to the same quarter last year. During the same period last year, the business posted ($1.40) EPS. Equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -3.75 earnings per share for the current year.

Institutional Trading of Alnylam Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in Alnylam Pharmaceuticals by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 11,994,261 shares of the biopharmaceutical company’s stock valued at $1,792,542,000 after purchasing an additional 50,366 shares during the period. Wellington Management Group LLP increased its stake in Alnylam Pharmaceuticals by 6.0% in the 3rd quarter. Wellington Management Group LLP now owns 6,431,814 shares of the biopharmaceutical company’s stock worth $1,139,074,000 after acquiring an additional 364,021 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Alnylam Pharmaceuticals by 5.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock worth $550,837,000 after acquiring an additional 201,784 shares during the last quarter. Capital International Investors increased its stake in Alnylam Pharmaceuticals by 1.8% in the 1st quarter. Capital International Investors now owns 3,651,217 shares of the biopharmaceutical company’s stock worth $545,674,000 after acquiring an additional 64,560 shares during the last quarter. Finally, Capital Research Global Investors increased its stake in Alnylam Pharmaceuticals by 7.3% in the 1st quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock worth $470,018,000 after acquiring an additional 214,908 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Analyst Ratings Changes

ALNY has been the topic of several recent analyst reports. Wells Fargo & Company increased their price objective on Alnylam Pharmaceuticals from $161.00 to $207.00 and gave the company an “equal weight” rating in a research report on Tuesday. Stifel Nicolaus increased their price objective on Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the company a “buy” rating in a research report on Thursday. Citigroup raised their target price on Alnylam Pharmaceuticals from $227.00 to $291.00 and gave the stock a “buy” rating in a research report on Tuesday. StockNews.com raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, April 29th. Finally, Chardan Capital reissued a “buy” rating and issued a $225.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, May 3rd. Eight analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $247.09.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.